Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4INDIV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 2419Neoplasms 1838Carcinoma, Non-Small-Cell Lung 1591Prostatic Neoplasms 1296Colorectal Neoplasms 1117Lung Neoplasms 981Neoplasm Metastasis 828Multiple Myeloma 793Leukemia, Myeloid, Acute 773Ovarian Neoplasms 673Pancreatic Neoplasms 667Melanoma 660Squamous Cell Carcinoma of Head and Neck 589Recurrence 563Carcinoma, Hepatocellular 562Brain Neoplasms 515Glioblastoma 505Stomach Neoplasms 501Head and Neck Neoplasms 492Triple Negative Breast Neoplasms 471Lymphoma 460Uterine Cervical Neoplasms 444Carcinoma, Renal Cell 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 420Lymphoma, Non-Hodgkin 387Endometrial Neoplasms 377Sarcoma 365Lymphoma, Follicular 357Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

pembrolizumab 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Cancer × 1 year × Clear all
NCT05947474 2026-02-10

ORB

Orionis Biosciences Inc

Phase 1 Active not recruiting
55 enrolled

Advanced Solid Cancer

NCT07265921 2025-12-05

Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting
232 enrolled

Advanced Solid Cancer

NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Aptabio Therapeutics, Inc.

Phase 1 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Cancer

NCT07196579 2025-09-29

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

TCRx Therapeutics Co.Ltd

Phase 1 Not yet recruiting
30 enrolled

Advanced Solid Cancer

NCT06985355 2025-09-18

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
200 enrolled

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡